Nano-carriers for drug routeing – towards a new era

References

• Couvreur P, Vauthier C. Nanotechnology: intelligent design to treat complex disease. Pharm Res. 2006;23:1417–1450.
   PubMed Web of Science ®Google Scholar
• Bazile D. 2018. Translation of nano-carriers from discovery to proof-of-concept in human – quality management based on the technology readiness levels. In: P. M. Moghimi, éd. Nanomedicine: exploring the potential of nano-therapeutics. s.l.:CRC Press, p. in press.
   Google Scholar
• Couvreur P, Kante B, Roland M, et al. Adsorption of antineoplastic drugs to polyalkylcyanoacrylate nanoparticles and their release in calf serum. J Pharm Sci. 1979;68:1521–1524.
   PubMed Web of Science ®Google Scholar
• Brasseur F, Couvreur P, Kante B, et al. Actinomycin D absorbed on polymethylcyanoacrylate nanoparticles: increased efficiency against an experimental tumor. Eur J Cancer. 1980;16:1441–1445.
   PubMed Web of Science ®Google Scholar
• Couvreur P, et al. 1984. Design of biodegradable polyalkylcyanoacrylate nanoparticles as a drug carrier: pharmaceutical, immunological, and medical aspects. In: S. Davis, éd. Microspheres and drug therapy. Amsterdam: Elsevier, pp. 103–115.
   Google Scholar
• Kreuter J. Nanoparticles—a historical perspective. Int J Pharm. 2007;331:1–10.
   PubMed Web of Science ®Google Scholar
• Damge C, Michel C, Aprahamian M, et al. New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carrier. Diabetes. 1988;37:246–251.
   PubMed Web of Science ®Google Scholar
• Aguirre TAS, Teijeiro-Osorio D, Rosa M. Current status of selected oral peptide technologies that are in advanced preclinical development and in clinical trials. Adv Drug Deliv Rev. 2016;106:223–241.
   PubMed Web of Science ®Google Scholar
• Yu M, Wu J, Shi J, et al. Nanotechnology for protein delivery: overview and perspectives. J Control Release. 2016;240:24–37.
   PubMed Web of Science ®Google Scholar
• Davis ME, Zuckerman JE, Choi CHJ, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010;464:1067–1070.
   PubMed Web of Science ®Google Scholar
• Frima H, Gabellieri C, Nilsson M. Drug delivery research in the European Union's Seventh Framework Programme for Research. J Control Release. 2012;161:409–415.
   PubMed Web of Science ®Google Scholar
• Lakkireddy H, et al. Oral delivery of diabetes peptides – Comparing standard formulations incorporating functional excipients and nanotechnologies in the translational context. Adv Drug Deliv Rev 2016.
   Web of Science ®Google Scholar
• Boxenbaum H. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm. 1982;10:201–227.
   PubMedGoogle Scholar
• Maeda H. Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. J Control Release. 2012;164:138–144.
   PubMed Web of Science ®Google Scholar
• Bertrand N, Wu J, Xu X, et al. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev. 2014;66:2–25.
   PubMed Web of Science ®Google Scholar
• Arranja A, Pathak V, Lammers T, et al. Tumor-targeted nanomedicines for cancer theranostics. Pharmacol Res. 2017;115:87–95.
   PubMed Web of Science ®Google Scholar
• Bosch F, Rosich L. The contributions of Paul Ehrlich to pharmacology: a tribute on the occasion of the centenary of his Nobel prize. Pharmacology. 2008;82:171–179.
   PubMed Web of Science ®Google Scholar
• Bertrand N, Leroux J-C. The journey of a drug-carrier in the body: an anatomo-physiological perspective. J Control Release. 2012;161:152–163.
   PubMed Web of Science ®Google Scholar
• Kutscher HL, Chao P, Deshmukh M, et al. Threshold size for optimal passive pulmonary targeting and retention of rigid microparticles in rats. J Control Release. 2010;143:31–37.
   PubMed Web of Science ®Google Scholar
• Choi HS, Liu W, Misra P, et al. Renal clearance of quantum dots. Nat Biotechnol. 2007;25:1165–1170.
   PubMed Web of Science ®Google Scholar
• Moghimi M, Hunter A, Murray J. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev. 2001;53:283–318.
   PubMed Web of Science ®Google Scholar
• Owens D, III, Peppas N. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm. 2006;307:93–102.
   PubMed Web of Science ®Google Scholar
• Szebeni J. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology. 2005;216:106–121.
   PubMed Web of Science ®Google Scholar
• Prabhakar U, Maeda H, Jain RK, et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res. 2013;73:2412–2417.
   PubMed Web of Science ®Google Scholar
• Weis S. Vascular permeability in cardiovascular disease and cancer. Curr Opin Hematol. 2008;15:243–249.
   PubMed Web of Science ®Google Scholar
• Harrington K, et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res. 2001;7:243–254.
   PubMed Web of Science ®Google Scholar
• Dvorak H, J A, N, Dvorak J, et al. Identfication and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol. 1988;133:95–109.,
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Watanabe R, Choyke P. Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target? Theranostics. 2014;4:81–89.
   Web of Science ®Google Scholar
• Daemen T, Hofstede G, Ten Kate MT, et al. Liposomal doxorubicin‐induced toxicity: depletion and impairment of phagocytic activity of liver macrophages. Int J Cancer. 1995;61:716–721.
   PubMed Web of Science ®Google Scholar
• Plard J-P, Bazile D. Comparison of the safety profiles of PLA50 and Me.PEG-PLA50 nanoparticles after single dose intravenous administration to rat. Colloids Surf B Biointerfaces. 1999;16:173–183.
   Web of Science ®Google Scholar
• Poulin P, Theil F-P. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. J Pharm Sci. 2002;91:1358–1370.
   PubMed Web of Science ®Google Scholar
• McWhorter FY, Davis CT, Liu WF. Physical and mechanical regulation of macrophage phenotype and function. Cell Mol Life Sci. 2015;72:1303–1316.
   PubMed Web of Science ®Google Scholar
• Jacobs F, Wisse E, De Geest B. The role of liver sinusoidal cells in hepatocyte-directed gene transfer. Am J Pathol. 2010;176:14–21.
   PubMed Web of Science ®Google Scholar
• Lawrence MG, Altenburg MK, Sanford R, et al. Permeation of macromolecules into the renal glomerular basement membrane and capture by the tubules. Proc Natl Acad Sci USA. 2017;114:2958–2963.
   PubMed Web of Science ®Google Scholar
• Sehgal A, Vaishnaw A, Fitzgerald K. Liver as a target for oligonucleotide therapeutics. J Hepatol. 2013;59:1354–1359.
   PubMed Web of Science ®Google Scholar
• Wisse E. An electron microscopic study of the fenestrated endothelial lining of rat liver sinusoids. J Ultrastruct Res. 1970;31:125–150.
   PubMedGoogle Scholar
• Braet F, Wisse E. Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review. Comp Hepatol. 2002;1:1–17.
   PubMedGoogle Scholar
• Wisse E, de Zanger RB, Charels K, et al. The liver sieve: considerations concerning the structure and function of endothelial fenestrae, the sinusoidal wall and the space of Disse. Hepatology. 1985;5:683–692.
   PubMed Web of Science ®Google Scholar
• Do H, Healey J, Waller E, et al. Expression of factor VIII by murine liver sinusoidal endothelial cells. J Biol Chem. 1999;274:19587–19592.
   PubMed Web of Science ®Google Scholar
• Shiratori Y, Tananka M, Kawase T, et al. Quantification of sinusoidal cell function in vivo. Semin Liver Dis. 1993;13:39–49.
   PubMed Web of Science ®Google Scholar
• Robinson MW, Harmon C, O'Farrelly C. Liver immunology and its role in inflammation and homeostasis. Cell Mol Immunol. 2016;13:267–276.
   PubMed Web of Science ®Google Scholar
• Li F, Wang J. Targeted delivery of drugs for liver fibrosis. Expert Opin Drug Deliv. 2009;6:531–541.
   PubMed Web of Science ®Google Scholar
• Alving C. Delivery of liposome-encapsulated drugs to macrophages. Pharmacol Ther. 1983;22:407–424.
   PubMed Web of Science ®Google Scholar
• Tacke F. Targeting hepatic macrophages to treat liver diseases. J Hepatol. 2017;66:1300–1312.
   PubMed Web of Science ®Google Scholar
• Alving CR, Steck EA, Chapman WL, et al. Therapy of leishmaniasis: superior efficacies of liposome-encapsulated drugs. Proc Nat Acad Sci USA. 1978;75:2959–2963.
   PubMed Web of Science ®Google Scholar
• Fattal E, Youssef M, Couvreur P, et al. Treatment of experimental salmonellosis in mice with ampicillin-bound nanoparticles. Antimicrob Agents Chemother. 1989;33:1540–1543.
   PubMed Web of Science ®Google Scholar
• Duong HTT, Dong Z, Su L, et al. The use of nanoparticles to deliver nitric oxide to hepatic stellate cells for treating liver fibrosis and portal hypertension. Small. 2015;11:2291–2304.
   PubMed Web of Science ®Google Scholar
• Toriyabe N, Sakurai Y, Kato A, et al. The delivery of small interfering RNA to hepatic stellate cells using a lipid nanoparticle composed of a vitamin A-scaffold lipid-like material. J Pharm Sci. 2017;106:2046–2052.
   PubMed Web of Science ®Google Scholar
• Yamada T, Iwasaki Y, Tada H, et al. Nanoparticles for the delivery of genes and drugs to human hepatocytes. Nat Biotechnol. 2003;21:885–890.
   PubMed Web of Science ®Google Scholar
• Barraud L, Merle P, Soma E, et al. Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo. J Hepatol. 2005;42:736–743.
   PubMed Web of Science ®Google Scholar
• Couvreur P, Kante B, Lenaerts V, et al. Tissue distribution of antitumor drugs associated with polyalkylcyanoacrylate nanoparticles. J Pharm Sci. 1980;69:199–202.
   PubMed Web of Science ®Google Scholar
• Couvreur P, Kante B, Grislain L, et al. Toxicity of polyalkylcyanoacrylate nanoparticles II: doxorubicin-loaded nanoparticles. J Pharm Sci. 1982;71:790–792.
   PubMed Web of Science ®Google Scholar
• Chiannilkulchai N, et al. Nanoparticles of doxorubicin: colloidal vectors in the treatment of hepatic metastases in animals. Bull Cancer. 1989;76:845–848.
   PubMed Web of Science ®Google Scholar
• Verdun C, Brasseur F, Vranckx H, et al. Tissue distribution of doxorubicin associated with polyisohexylcyanoacrylate nanoparticles. Cancer Chemother Pharmacol. 1990;26:13–18.
   PubMed Web of Science ®Google Scholar
• Trochon-Joseph V, et al. 2016. Mechanistic study of the relative cytotoxicity of doxorubicin loaded nanoparticle formulation compared to free doxorubicin in hepatocellular carcinoma (HCC) cell lines. AACR Annual Meeting, New Orleans, Louisiana, USA, Volume April 16-20, p. Abstract 2143.
   Google Scholar
• de Verdière AC, Dubernet C, Némati F, et al. Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: towards a mechanism of action. Br J Cancer. 1997;76:198–205.
   PubMed Web of Science ®Google Scholar
• Merle P, Si Ahmed S, Habersetzer F, et al. Phase 1 study of intra-arterial hepatic (IAH) delivery of doxorubicin-transdrug (DT) for patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol. 2006;24:14094.
   Google Scholar
• Bioalliance, 2009. Doxorubicin Transdrug: significant increased survival rate in patients with advanced hepatocellular carcinoma treated in a phase II clinical trial. Bioalliance web document.
   Google Scholar
• Onxeo 2017. Onxeo Announces Top-Line Results from ReLive Phase III Study of Livatag® in Advanced Hepatocellular Carcinoma. [En ligne] Available at: https://www.onxeo.com/onxeo-announces-top-line-results-relive-phase-iii-study-livatag-advanced-hepatocellular-carcinoma/ [Accès le 5 December 2018].
   Google Scholar
• Love KT, Mahon KP, Levins CG, et al. Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci USA. 2010;107:1864–1869.
   PubMed Web of Science ®Google Scholar
• Akinc A, Goldberg M, Qin J, et al. Development of lipidoid-siRNA formulations for systemic delivery to the liver. Mol Ther. 2009;17:872–879.
   PubMed Web of Science ®Google Scholar
• Schroeder A, Levins CG, Cortez C, et al. Lipid-based nanotherapeutics for siRNA delivery. J Intern Med. 2010;267:9–21.
   PubMed Web of Science ®Google Scholar
• Wang J, Lu Z, Wientjes M, et al. Delivery of siRNA therapeutics: barriers and carriers. AAPS J. 2010;12:492–503.
   PubMed Web of Science ®Google Scholar
• Semple SC, Akinc A, Chen J, et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol. 2010;28:172–176.
   PubMed Web of Science ®Google Scholar
• Wan C, Allen T, Cullis P. Lipid nanoparticle delivery systems for siRNA-based therapeutics. Drug Deliv and Transl Res. 2014;4:74–83.
   PubMed Web of Science ®Google Scholar
• Cheng X, Lee R. The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery. Adv Drug Deliv Rev. 2016;99:129–137.
   PubMed Web of Science ®Google Scholar
• Snoeys J, Lievens J, Wisse E, et al. Species differences in transgene DNA uptake in hepatocytes after adenoviral transfer correlate with the size of endothelial fenestrae. Gene Ther. 2007;14:604–612.
   PubMed Web of Science ®Google Scholar
• Lievens J, Snoeys J, Vekemans K, et al. The size of sinusoidal fenestrae is a critical determinant of hepatocyte transduction after adenoviral gene transfer. Gene Ther. 2004;11:1523–1531.
   PubMed Web of Science ®Google Scholar
• Sato Y, Note Y, Maeki M, et al. Elucidation of physicochemical properties and potency of siRNA-loaded small-sized lipid nanoparticles for siRNA delivery. J Cont Rel. 2016;229:48–57.
   PubMed Web of Science ®Google Scholar
• Chen S, Tam YYC, Lin PJC, et al. Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA. J Control Release. 2016;235:236–244.
   PubMed Web of Science ®Google Scholar
• Watanabe T. In vivo therapeutic potential of Dicer-hunting siRNAs targeting infectious hepatitis C virus. Scientific Reports. 2014;4:1–11.
   Web of Science ®Google Scholar
• Jayaraman M, Ansell SM, Mui BL, et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew Chem Int Ed Engl. 2012;51:8529–8533.
   PubMed Web of Science ®Google Scholar
• Maier MA, Jayaraman M, Matsuda S, et al. Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol Ther. 2013;21:1570–1578.
   PubMed Web of Science ®Google Scholar
• Zimmermann TS, Lee ACH, Akinc A, et al. RNAi-mediated gene silencing in non-human primates. Nature. 2006;441:111–114.
   PubMed Web of Science ®Google Scholar
• Frank-Kamenetsky M, Grefhorst A, Anderson NN, et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. PNAS. 2008;105:11915–11920.
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Lee ACH, Robbins M, et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet. 2010;375:1896–1905.
   PubMed Web of Science ®Google Scholar
• Yu B, Hsu S-H, Zhou C, et al. Lipid nanoparticles for hepatic delivery of small interfering RNA. Biomaterials. 2012;33:5924–5934.
   PubMed Web of Science ®Google Scholar
• Zhang J, Pei Y, Zhang H, et al. Assessing the heterogeneity level in lipid nanoparticles for siRNA delivery: size-based separation, compositional heterogeneity, and impact on bioperformance. Mol Pharmaceutics. 2013;10:397–405.
   PubMed Web of Science ®Google Scholar
• Mui BL, Tam YK, Jayaraman M, et al. Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles. Mol Ther Nucliec Acids. 2013;2:e139.
   Google Scholar
• Akinc A, Querbes W, De S. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligandbased mechanisms. Mol Ther. 2010;18:1357–1364.
   PubMed Web of Science ®Google Scholar
• Song LY, Ahkong QF, Rong Q, et al. Characterization of the inhibitory effect of PEG-lipid conjugates on the intracellular delivery of plasmid and antisense DNA mediated by cationic lipid liposomes. Biochim Biophys Acta. 2002;1558:1–13.
   PubMed Web of Science ®Google Scholar
• Tam Y, Chen S, Cullis P. Advances in lipid nanoparticles for siRNA delivery. Pharmaceutics. 2013;5:498–507.
   PubMedGoogle Scholar
• Nechev L, Price S. 2015. Compositions and methods for the manufacture of lipid nanoparticles. USA, Brevet n° WO 2015/048020 A2.
   Google Scholar
• Gertz MA, Benson MD, Dyck PJ, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol. 2015;66:2451–2466.
   PubMed Web of Science ®Google Scholar
• Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013;369:819–829.
   PubMed Web of Science ®Google Scholar
• Suhr O, et al. Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study. Orphanet J Rare Dis. 2015;10:109.
   PubMed Web of Science ®Google Scholar
• Adams D, Suhr OB, Dyck PJ. Trial design and rationale for APOLLO, a phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurol. 2017;17:181.
   PubMed Web of Science ®Google Scholar
• Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:11–21.
   PubMed Web of Science ®Google Scholar
• Amidon G, Lennernäs H, Shah V, et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413–420.
   PubMed Web of Science ®Google Scholar
• Orfi E, Szebeni J. The immune system of the gut and potential adverse effects of oral nanocarriers on its function. Adv Drug Deliv Rev. 2016;106:402–409.
   PubMed Web of Science ®Google Scholar
• Jani P, Halbert G, Langridge J, et al. Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency. J Pharm Pharmacol. 1990;42:821–826.
   PubMed Web of Science ®Google Scholar
• Presas E, McCartney F, Sultan E, et al. Physicochemical, pharmacokinetic and pharmacodynamic analyses of amphiphilic cyclodextrin-based nanoparticles designed to enhance intestinal delivery of insulin. J Control Release. 2018;286:402–414.
   PubMed Web of Science ®Google Scholar
• Maher S, Mrsny R, Brayden D. Intestinal permeation enhancers for oral peptide delivery. Adv Drug Deliv Rev. 2016;106:277–319.
   PubMed Web of Science ®Google Scholar
• Baluom M, Friedman M, Rubinstein A. The importance of intestinal residence time of absorption enhancer on drug absorption and implication on formulative considerations. Int J Pharm. 1998;176:21–30.
   Google Scholar
• Bazile D, Prud'homme C, Bassoullet M‐T, et al. Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J Pharm Sci. 1995;84:493–498.
   PubMed Web of Science ®Google Scholar
• Vittaz M, Bazile D, Spenlehauer G, et al. Effect of PEO surface density on long-circulating PLA-PEO nanoparticles which are very low complement activators. Biomaterials. 1996;17:1575–1561.
   PubMed Web of Science ®Google Scholar
• Nicolas J, Mura S, Brambilla D, et al. Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery. Chem Soc Rev. 2013;42:1147–1235.
   PubMed Web of Science ®Google Scholar
• Hrkach J, Von Hoff D, Ali MM, et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med. 2012;4:128ra39.
   PubMed Web of Science ®Google Scholar
• Pridgen EM, Alexis F, Kuo TT, et al. Transepithelial transport of Fc-targeted nanoparticles. Sci Trans Med. 2013;5:213ra167.
   PubMed Web of Science ®Google Scholar
• Adler A, Leong K. Emerging links between surface nanotechnology and endocytosis: impact on nonviral gene delivery. Nano Today. 2010;5:553–569.
   PubMed Web of Science ®Google Scholar
• Tan P, Luscinskas F, Homer-Vanniasinkam S. Cellular and molecular mechanisms of inflammation and thrombosis. Eur J Vasc Endovasc Surg. 1999;17:373–389.
   PubMed Web of Science ®Google Scholar
• Dobrovolskaia M, McNeil S. Immunological properties of engineered nanomaterials. Nat Nanotechnol. 2007;2:469–478.
   PubMed Web of Science ®Google Scholar
• Aula S, Lakkireddy S, Jamil K, et al. Biophysical, biopharmaceutical and toxicological significance of biomedical nanoparticles. RSC Adv. 2015;5:47830–47859.
   Web of Science ®Google Scholar
• Landry FB, Bazile DV, Spenlehauer G, et al. Release of the fluorescent marker ProdanR from poly(d,l-lactic acid) nanoparticles coated with albumin or polyvinyl alcohol in model digestive fluids (USP XXII). J Control Release. 1997;44:227–236.
   Web of Science ®Google Scholar
• Tobio M, et al. The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration. Colloids Surf B Biointerfaces. 2000;18:315–323.
   PubMed Web of Science ®Google Scholar
• Hussain N, Jaitley V, Florence A. Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics. Adv Drug Deliv Rev. 2001;50:107–142.
   PubMed Web of Science ®Google Scholar
• Lakkireddy H, Bazile D. Building the design, translation and development principles of polymeric nanomedicines using the case of clinically advanced poly(lactide(glycolide))–poly(ethylene glycol) nanotechnology as a model: an industrial viewpoint. Adv Drug Deliv Rev. 2016;107:289–332.
   PubMed Web of Science ®Google Scholar
• Zolnik B, Sadrieh N. Regulatory perspective on the importance of ADME assessment of nanoscale material containing drugs. Adv Drug Deliv Rev. 2009;61:422–427.
   PubMed Web of Science ®Google Scholar
• Harashima H, Iida S, Urakami Y, et al. Optimization of antitumor effect of liposomally encapsulated doxorubicin based on simulations by pharmacokinetic/pharmacodynamic modeling. J Control Release. 1999;61:93–106.
   PubMed Web of Science ®Google Scholar
• Stern ST, Hall JB, Yu LL, et al. Translational considerations for cancer nanomedicine. J Control Release. 2010;146:164–174.
   PubMed Web of Science ®Google Scholar
• Zeng L, An L, Wu X,. Modeling drug-carrier interaction in the drug release from nanocarriers. J Drug Deliv. 2011;2011:1–15.
   Google Scholar
• Emile C, Bazile D, Herman F, et al. Encapsulation of oligonucleotides in stealth Me.PEG-PLA50 nanoparticles by complexation with structured oligopeptides. Drug Deliv. 1996;3:187–195.
   PubMedGoogle Scholar
• Harada A, Kataoka K. Pronounced activity of enzymes through the incorporation into the core of polyion complex micelles made from charged block copolymers. J Control Release. 2001;72:85–91.
   PubMed Web of Science ®Google Scholar
• Perez C, Sanchez A, Putnam D, et al. Poly(lactic acid)-poly(ethylene glycol) nanoparticles as new carriers for the delivery of plasmid DNA. J Control Release. 2001;75:211–224.
   PubMed Web of Science ®Google Scholar
• Giovino C, Ayensu I, Tetteh J, et al. Development and characterisation of chitosan films impregnated with insulin loaded PEG-b-PLA nanoparticles (NPs): a potential approach for buccal delivery of macromolecules. Int J Pharm. 2012;428:143–151.
   PubMed Web of Science ®Google Scholar
• Diou O, Greco S, Beltran T, et al. A method to quantify the affinity of cabazitaxel for PLA-PEG nanoparticles and investigate the influence of the nano-assembly structure on the drug/particle association. Pharm Res. 2015;32:3188–3200.
   PubMed Web of Science ®Google Scholar
• Verrecchia T. 1998. Mécanisme de libération in vitro d'une molécule hydrophobe encapsulée dans des nanoparticules d'un co-polymère de poly(acide lactique) et de poly(ethylène glycol) [PLAPEG], s.l.: s.n.
   Google Scholar
• Panyam J, Williams D, Dash A, et al. Solid-state solubility influences encapsulation and release of hydrophobic drugs from PLGA/PLA nanoparticles. J Pharm Sci. 2004;93:1804–1814.
   PubMed Web of Science ®Google Scholar
• Lenaerts V, Couvreur P, Christiaens-Leyh D, et al. Degradationo f poly (isobutyl cyanoacrylate) nanoparticles. Biomaterials. 1984;5:65–68.
   PubMed Web of Science ®Google Scholar
• Grangier J-L, Puygrenier M, Gautier J, et al. Nanoparticles as carriers for growth hormone releasing factor. J Control Release. 1991;15:3–13.
   Web of Science ®Google Scholar
• Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nature Mater. 2013;12:991–1003.
   PubMed Web of Science ®Google Scholar
• Ulbrich K, Subr V. Polymeric anticancer drugs with pH-controlled activation. Adv Drug Deliv Rev. 2004;56:1023–1050.
   PubMed Web of Science ®Google Scholar
• Zou J, Zhang F, Zhang S, et al. Poly(ethylene oxide)-block-polyphosphoester-graft-paclitaxel conjugates with acid-labile linkages as a pH-sensitive and functional nanoscopic platform for paclitaxel delivery. Adv Healthcare Mater. 2014;3:441–448.
   Web of Science ®Google Scholar
• Choy C, Geruntho J, Davis A, et al. Tunable pH-sensitive linker for controlled release. Bioconjugate Chem. 2016;27:824–830.
   PubMed Web of Science ®Google Scholar
• Schafer F, Buettner G. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med. 2001;30:1191–1212.
   PubMed Web of Science ®Google Scholar
• Meng F, Hennink W, Zhong Z. Reduction-sensitive polymers and bioconjugates for biomedical applications. Biomaterials. 2009;30:2180–2198.
   PubMed Web of Science ®Google Scholar
• Han H, Valdepérez D, Jin Q, et al. Dual enzymatic reaction-assisted gemcitabine delivery systems for programmed pancreatic cancer therapy. ACS Nano. 2017;11:1281–1291.
   PubMed Web of Science ®Google Scholar
• Li H, Wang P, Deng Y, et al. Combination of active targeting, enzyme-triggered release and fluorescent dye into gold nanoclusters for endomicroscopy-guided photothermal/photodynamic therapy to pancreatic ductal adenocarcinoma. Biomaterials. 2017;139:30–38.
   PubMed Web of Science ®Google Scholar
• Tong R, Tang L, Ma L, et al. Smart chemistry in polymeric nanomedicine. Chem Soc Rev. 2014;43:6982–7012.
   PubMed Web of Science ®Google Scholar
• Yuan Y, Zhang C-J, Xu S, et al. A self-reporting AIE probe with a built-in singlet oxygen sensor for targeted photodynamic ablation of cancer cells. Chem Sci. 2016;7:1862–1866.
   PubMed Web of Science ®Google Scholar
• Bensaid F, Thillaye du Boullay O, Amgoune A, et al. Y-Shaped mPEG-PLA cabazitaxel conjugates: well-controlled synthesis by organocatalytic approach and self-assembly into interface drug-loaded core − corona nanoparticles. Biomacromolecules. 2013;14:1189–1198.
   PubMed Web of Science ®Google Scholar
• Lakkireddy HBD. Drug delivery design for intravenous route with integrated physicochemistry, pharmacokinetics and pharmacodynamics: Illustration with the case of taxane therapeutics. Adv Drug Deliv Rev. 2014;71:34–57.
   PubMed Web of Science ®Google Scholar
• Lim J, Karnik R. Optimizing the discovery and clinical translation of nanoparticles: could microfluidics hold the key? Nanomedicine (Lond). 2014;9:1113–1116.
   PubMed Web of Science ®Google Scholar
• Colombo S, Beck-Broichsitter M, Bøtker JP, et al. Transforming nanomedicine manufacturing toward quality by design and microfluidics. Adv Drug Deliv Rev. 2018;128:115–131.
   PubMed Web of Science ®Google Scholar
• Kang X, Luo C, Wei Q, et al. Mass production of highly monodisperse polymeric nanoparticles by parallel flow focusing system. Microfluid Nanofluid. 2013;15:337–345.
   Web of Science ®Google Scholar
• Li X, Jiang X. Microfluidics for producing poly (lactic-co-glycolic acid)-based pharmaceutical nanoparticles. Adv Drug Deliv Rev. 2018;128:101–114.
   PubMed Web of Science ®Google Scholar
• Bazile DV. Nanotechnologies in drug delivery – an industrial perspective. J Drug Deliv Sci Tech. 2014;24:12–21.
   Web of Science ®Google Scholar
• Desgouilles S, Vauthier C, Bazile D, et al. The design of nanoparticles obtained by solvent evaporation: a comprehensive study. Langmuir. 2003;19:9504–9510.
   Web of Science ®Google Scholar
• Meunier M, Goupil A, Lienard P. Predicting drug loading in PLA-PEG nanoparticles. Int J Pharm. 2017;526:157–166.
   PubMedGoogle Scholar
• Eaton M, Levy L, Fontaine O. Delivering nanomedicines to patients: a practical guide. Nanomedicine. 2015;11:983–992.
   PubMed Web of Science ®Google Scholar
• Gautam A, Pan X. The changing model of big pharma: impact of key trends. Drug Disc Today. 2016;21:379–384.
   PubMed Web of Science ®Google Scholar
• FDA, 2017. Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices, s.l.: USFDA.
   Google Scholar
• Krause J, Saver R. Real-world evidence in the real world: beyond the FDA. Am J Law Med. 2018;44:161–179.
   PubMed Web of Science ®Google Scholar
• Lorenzer C, Dirin M, Winkler A-M, et al. Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics. J Control Release. 2015;203:1–15.
   PubMed Web of Science ®Google Scholar
• Passaro F, Testa G, Ambrosone L, et al. Nanotechnology-based cardiac targeting and direct cardiac reprogramming: the betrothed. Stem Cells Int. 2017;2017:1–12.
   Google Scholar
• Rhee J-W, Wu J. Advances in nanotechnology for the management of coronary artery disease. Trends Cardiovasc Med. 2013;23:39–45.
   PubMed Web of Science ®Google Scholar
• Ambesh P, Campia U, Obiagwu C, et al. Nanomedicine in coronary artery disease. Indian Heart J. 2017;69:244–251.
   PubMedGoogle Scholar
• Saraiva C, Praça C, Ferreira R, et al. Nanoparticle-mediated brain drug delivery: overcoming blood–brain barrier to treat neurodegenerative diseases. J Control Release. 2016;235:34–47.
   PubMed Web of Science ®Google Scholar
• Grabrucker A, et al. Nanoparticle transport across the blood brain barrier. Tissue Barriers. 2016;4:1–18.
   Web of Science ®Google Scholar
• Brambilla D, Le Droumaguet B, Nicolas J, et al. Nanotechnologies for Alzheimer's disease: diagnosis, therapy, and safety issues. Nanomedicine. 2011;7:521–540.
   PubMed Web of Science ®Google Scholar
• Matilda A, Oskari E, Topias S, et al. A review on ophthalmology using nanotechnology. J Nanomed Nanotechnol. 2015;272:6.
   Google Scholar
• Cetinel S, Montemagno C. Nanotechnology applications for glaucoma. Asia Pac J Ophthalmol (Phila). 2016;5:70–78.
   PubMed Web of Science ®Google Scholar
• Cevc G, Vierl U. Nanotechnology and the transdermal route: a state of the art review and critical appraisal. J Control Release. 2010;141:277–299.
   PubMed Web of Science ®Google Scholar